Indian pharmacists inspecting medicine inventory.
India’s drug regulator is intensifying its oversight of the GLP-1 supply chain in response to growing concerns about misuse, according to recent reports. The move follows nationwide inspections of pharmacies and clinics aimed at curbing the illegal sale of these specialized weight loss drugs.
Authorities are also cracking down on unapproved drug combinations as part of a broader effort to ensure patient safety and regulatory compliance across the pharmaceutical supply chain. The increased vigilance includes more stringent checks on the sales and distribution of weight loss medications.
The regulatory actions reflect a commitment to enforcing pharmaceutical regulations and safeguarding public health amid rising demand for GLP-1 receptor agonists, which have gained popularity for their effectiveness in weight management and diabetes treatment. The focus remains on preventing the misuse of these drugs and ensuring that they are prescribed and dispensed appropriately.
About the Author
